Experts Discuss Effects of Cancer on Memory and Thinking at Free Symposium

CINCINNATI—The University of Cincinnati Cancer and Neuroscience Institutes are holding a free seminar Saturday, Sept. 12, to educate patients and the community on the effect of cancer therapy on memory loss and critical thinking.

The event, which will take place from 8 a.m. to noon, will involve presentations from and interactive discussions with oncology and neuroscience experts.

"The diagnosis of cancer is accompanied by fear and uncertainty, and while much of the focus is on the prognosis of the disease, the perceived effects of the treatment also cause a great deal of anxiety,” says Luke Pater, MD, a UC Health radiation oncologist, assistant professor at UC and member of the institutes who is speaking at the event.

"Neurocognitive effects of anti-cancer therapies have long been recognized. The term ‘chemobrain’ has been assigned to cognitive delays that patients experience following the administration of chemotherapy. A greater understanding of how different doses of radiation and exposures to different regions of the brain have evolved which has led to new approaches in how patients are treated to minimize side-effects on memory and cognition. 

"We hope that this event will educate patients on advances being made in this regard and allow them to ask questions about both cancer treatment and effects.”

In addition to a presentation by Pater which will focus on ways to minimize cognitive changes after radiotherapy, experts will discuss memory loss and cancer, mood and mental functioning, the effect of chemotherapy on the brain and ways to minimize cognitive changes after radiotherapy. A free continental breakfast will be offered for attendees.

>> See the full agenda and register 

With questions, contact Karen Ramos at 513-558-1530.

Tags

Related Stories

2

At least two weather patterns increase headaches, UC study suggests

June 4, 2026

University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.